Peter Kirkbride, MB, BS, trained in medicine at University College London, UK, receiving his MB, BS degree in 1980. Following this, he trained in general medicine and then clinical oncology in the UK. In 1991, he was appointed as Staff Radiation Oncologist at Princess Margaret Hospital, Toronto, ON, Canada.

In 1999, he returned to the UK, to become a consultant in clinical oncology, specialising in urological cancers, at Weston Park Hospital, Sheffield. Subsequently, he also took on the roles of Clinical Director for Radiation Services, Cancer Lead Clinician for Sheffield Teaching Hospitals Trust, and Lead Clinician for the North Trent Cancer Network. In 2006, in these roles, he undertook a review of multidisciplinary teams working in Sheffield. He has been the Medical Director at the Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, since 2012.

Dr Kirkbride was the Lead Clinician for the National Institute for Health and Care Excellence (NICE) Prostate Cancer Guideline in 2014, the National Clinical Lead for Radiotherapy for the National Health Service (NHS) Improvement/National Cancer Action Team between 2002 and 2013, and a member of the National Radiotherapy Advisory Group and the National Radiotherapy Implementation Group; further, he is a past chair of the Radiotherapy Clinical Reference Group for the NHS in England. He is currently the National Lead for the Serious Illness Care Programme in the UK.

All rights reserved © 2018
HQ/ONCO/18/0003 | Preparation date: October 2018
Reporting of suspected adverse events is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
To ensure correct adverse event reporting, healthcare professionals are encouraged to use the appropriate website for their national authority.